Co-Authors
This is a "connection" page, showing publications co-authored by VIVEK SUBBIAH and JOSEPH A LUDWIG.
Connection Strength
3.357
-
Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res. 2018 10 01; 24(19):4865-4873.
Score: 0.635
-
Review: Ewing sarcoma treatment: a role for bisphosphonates? Clin Adv Hematol Oncol. 2010 Jul; 8(7):503-4.
Score: 0.367
-
Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010 Jun; 21(6):1041-5.
Score: 0.343
-
Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol. 2009 Apr; 10(1-2):126-40.
Score: 0.341
-
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
Score: 0.223
-
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
Score: 0.219
-
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel). 2020 Jul 02; 12(7).
Score: 0.183
-
Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
Score: 0.166
-
Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist. 2018 03; 23(3):360-366.
Score: 0.153
-
Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2017 08 01; 23(15):4027-4034.
Score: 0.146
-
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
Score: 0.142
-
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
Score: 0.141
-
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
Score: 0.141
-
Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol. 2010 Mar 15; 101(4):327-33.
Score: 0.090
-
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
Score: 0.036
-
Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One. 2014; 9(8):e93676.
Score: 0.030